Concizumab | Interleukin Related interleukin-related.com

Product Name :
Concizumab

Search keywords :
Tissue Factor

drugId :
null

Target Vo:
Tissue factor pathway inhibitor

Target Vo Short Name :
TFPI

Moa_Name:
Tissue factor pathway inhibitor inhibitors

First Approval Country :
Canada

First Approval Date Filter:
2023

Origin Company_Name :
Novo Nordisk A/S

Active Company_Name :
Novo Nordisk A/S

Active Indication_Name:
Hemophilia A

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
DNA-PKcs/PRKDC Antibody
PI3 Kinase p55 gamma Antibody
Histone H4 Antibody: Histone H4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 11 kDa, targeting to Histone H4. It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts